Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. Academic Article uri icon

Overview

abstract

  • Introduction: Qualitative analysis of Twitter posts reveals key insights about user norms, informedness, perceptions, and experiences related to opioid use disorder (OUD). This paper characterizes Twitter message content pertaining to medications for opioid use disorder (MOUD) and Naloxone.Methods: In-depth thematic analysis was conducted of 1,010 Twitter messages collected in June 2019. Our primary aim was to identify user perceptions and experiences related to harm reduction (e.g., Naloxone) and MOUD (e.g., sublingual and Extended-release buprenorphine, Extended-release naltrexone, Methadone).Results: Tweets relating to OUD were most commonly authored by general Twitter users (43.8%), private residential or detoxification programs (24.6%), healthcare providers (e.g., physicians, first responders; 4.3%), PWUOs (4.7%) and their caregivers (2.9%). Naloxone was mentioned in 23.8% of posts and authored most commonly by general users (52.9%), public health experts (7.4%), and nonprofit/advocacy organizations (6.6%). Sentiment was mostly positive about Naloxone (73.6%). Commonly mentioned MOUDs in our search consisted of Buprenorphine-naloxone (13.8%), Methadone (5.7%), Extended-release naltrexone (4.1%), and Extended-release buprenorphine (0.01%). Tweets authored by PWUOs (4.7%) most commonly related to factors influencing access to MOUD or adverse events related to MOUD (70.8%), negative or positive experiences with illicit substance use (25%), policies related to expanding access to treatments for OUD (8.3%), and stigma experienced by healthcare providers (8.3%).Conclusion: Twitter is utilized by a diverse array of individuals, including PWUOs, and offers an innovative approach to evaluate experiences and themes related to illicit opioid use, MOUD, and harm reduction.

publication date

  • August 24, 2020

Research

keywords

  • Analgesics, Opioid
  • Buprenorphine, Naloxone Drug Combination
  • Naloxone
  • Narcotic Antagonists
  • Opioid-Related Disorders
  • Perception
  • Social Media

Identity

PubMed Central ID

  • PMC8283817

Scopus Document Identifier

  • 85089783471

Digital Object Identifier (DOI)

  • 10.1080/10550887.2020.1811456

PubMed ID

  • 32835641

Additional Document Info

volume

  • 39

issue

  • 1